Teva Accupril Generic Delayed Until 2007; Pfizer Patent Is Valid, Court Says

If upheld on appeal, the decision would eliminate Teva’s 180-day exclusivity period and make a challenge to Pfizer’s own generic moot. A New Jersey federal judge finds there was no inequitable conduct before the PTO regarding Pfizer’s patent for its ACE inhibitor.